The DAIICHI SANKYO Group continues to create innovative pharmaceuticals and aims to expand its business focusing on pharmaceuticals to major areas of the world by 2015. To achieve this, we have set Vision 2015 with net sales of 1.5 trillion yen, an operating profit margin of at least 25%, and an overseas net sales ratio of at least 60%.

As a first step toward achieving Vision 2015, we have developed a three-year mid-term business management plan for 2007 to 2009. We are determined to exert the synergy effect of the business integration at the earliest date possible, and focus on strengthening our capabilities to create new drugs and expanding and enhancing our operating bases for further growth. Our business targets for 2009 are net sales of 960 billion and an operating income of 240 billion yen (operating profit margin of 25%). Furthermore, as a mid-term policy for shareholder returns, we plan to achieve at least 5% of DOE as early as possible, a steady increase in dividends and the acquisition of treasury stocks, with a total return ratio of 100% as our goal, which allocates free cash flow of the current fiscal period to dividends and the flexible acquisition of treasury stocks.

The DAIICHI SANKYO Group strives to gain more confidence from society at large and continues to provide more substantial information to our shareholders and investors both at home and abroad.

Thank you for your continued understanding and support.